Literature DB >> 26134428

Nitric Oxide, Inflammation, Lipid Profile, and Cortisol in Normal- and Overweight Women With Fibromyalgia.

Alma Rus1, Francisco Molina2, Manuela Gassó3, Maria Victoria Camacho3, Maria Ángeles Peinado4, Maria Luisa del Moral4.   

Abstract

OBJECTIVES: Research has identified many factors associated with fibromyalgia (FM), but findings have been inconsistent. This study aimed to investigate changes in levels of nitric oxide (NO), inflammatory markers, lipid profile, and cortisol in normal- and overweight patients with FM and controls. Since most patients with FM are overweight, we explored possible changes in these markers according to body mass index (BMI).
METHODS: This preliminary study was performed on serum samples of women with FM and age-matched controls, grouped according to their BMI: 12 normal-weight patients and 12 controls and 13 overweight patients and 8 controls. Ozone-based chemiluminescence assay was used to measure NO. Inflammatory mediators and cortisol were determined by immunoassay. Lipid profile was measured by a spectrophotometric procedure. Functional capacity was assessed by the fibromyalgia impact questionnaire (FIQ).
RESULTS: Normal-weight patients showed higher levels of C-reactive protein (CRP) and apolipoprotein B compared to controls (both p < .05). CRP, apolipoprotein B, and triglycerides were higher in overweight patients versus overweight controls (all p < .05) and in overweight versus normal-weight patients (CRP p < .01; apolipoprotein B, triglycerides p < .05). The other markers were unaffected. Apolipoprotein B (r = .762; p < .05) and NO (r = -.921; p < .05) levels correlated with FIQ score in normal-weight patients. CRP level correlated with FIQ (r = .912; p < .05) in overweight patients.
CONCLUSIONS: CRP and apolipoprotein B, biomarkers linked to cardiovascular events, may be associated with FM-related dysfunction in normal- and overweight women with FM. Their increased levels in these patients may indicate an increased risk of cardiovascular disease.
© The Author(s) 2015.

Entities:  

Keywords:  C-reactive protein; apolipoprotein B; fibromyalgia; overweight

Mesh:

Substances:

Year:  2015        PMID: 26134428     DOI: 10.1177/1099800415591035

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  6 in total

1.  Potential Mediators between Fibromyalgia and C-Reactive protein: Results from a Large U.S. Community Survey.

Authors:  Termeh Feinberg; Usha Sambamoorthi; Christa Lilly; Kim Karen Innes
Journal:  BMC Musculoskelet Disord       Date:  2017-07-07       Impact factor: 2.362

2.  Functional Status and Body Mass Index in Postmenopausal Women with Fibromyalgia: A Case-control Study.

Authors:  Laura Cerón Lorente; María Carmen García Ríos; Santiago Navarro Ledesma; Rosa María Tapia Haro; Antonio Casas Barragán; María Correa-Rodríguez; María Encarnación Aguilar Ferrándiz
Journal:  Int J Environ Res Public Health       Date:  2019-11-16       Impact factor: 3.390

Review 3.  Application of Salivary Biomarkers in the Diagnosis of Fibromyalgia.

Authors:  Rebeca Illescas-Montes; Víctor J Costela-Ruiz; Lucía Melguizo-Rodríguez; Elvira De Luna-Bertos; Concepción Ruiz; Javier Ramos-Torrecillas
Journal:  Diagnostics (Basel)       Date:  2021-01-03

Review 4.  Exploiting Common Aspects of Obesity and Alzheimer's Disease.

Authors:  Sidra Tabassum; Afzal Misrani; Li Yang
Journal:  Front Hum Neurosci       Date:  2020-12-15       Impact factor: 3.169

5.  Elevated highly sensitive C-reactive protein in fibromyalgia associates with symptom severity.

Authors:  Teemu Zetterman; Ritva Markkula; Eija Kalso
Journal:  Rheumatol Adv Pract       Date:  2022-06-25

6.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.